| Ytd | -34.97% | |
| 1y | -51.92% |
| Open | 1.26 | Prev Close | 1.25 | Low | 1.19 | High | 1.26 | Mkt Cap | 11.90M |
| Vol | 163.83K | Avg Vol | 420.12K | EPS | -0.95 | P/E | -1.32 | Forward P/E | -2.35 |
| Beta | 1.03 | Short Ratio | 0.64 | Inst. Own | 7.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.13 | 200-d Avg | 1.98 | 1yr Est | 21.33 |
DARE News
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven
Live video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's He
First consumer health product positions Daré for revenue generation while expanding its women's heal
President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding aw
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — a
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial
Shares of Dare Bioscience, Inc. (NASDAQ:DARE) are trading higher on Tuesday as the company is report
Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovapre
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.02 per share versus the Zacks Cons
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health S
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her DARE to PLAY™ Silde
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through Novembe
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND f
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with
During Wednesday's trading, 517 companies set new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report
Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018